Site-specific metastases of intrahepatic cholangiocarcinoma and its impact on survival: a population-based study

Future Oncol. 2019 Jun;15(18):2125-2137. doi: 10.2217/fon-2018-0846. Epub 2019 Jun 4.


Aim: Limited data exist on impact of the metastatic sites on survival in patients with metastatic intrahepatic cholangiocarcinoma (ICC). Methods: Patients with metastatic ICC were identified in the SEER from 2010 to 2015. Results: A total of 981 patients were identified, of this population, liver (57.9%) is the most common site of ICC metastases, followed by lung, bone and brain. Respective median overall survival and cancer-specific survival were 6 and 9 months in entire population. Further analysis suggested that patients treated by surgery to primary and/or metastatic lesions had a better survival outcome than patients had no surgery (p ≤ 0.001). Conclusion: Liver is the most common site for ICC metastases, local treatment such as surgery to primary or metastatic lesions obviously benefit patients.

Keywords: SEER; intrahepatic cholangiocarcinoma; metastasis; prognosis; surgery.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bile Duct Neoplasms / epidemiology
  • Bile Duct Neoplasms / mortality*
  • Bile Duct Neoplasms / pathology*
  • Bile Duct Neoplasms / therapy
  • Cholangiocarcinoma / epidemiology
  • Cholangiocarcinoma / mortality*
  • Cholangiocarcinoma / pathology*
  • Cholangiocarcinoma / therapy
  • Combined Modality Therapy
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Organ Specificity
  • Population Surveillance
  • Prognosis
  • SEER Program
  • United States / epidemiology